Allogeneic hematopoietic cell transplantation involves consideration of both donor and
recipient characteristics to guide the selection of a suitable graft. Sufficient high-resolution …

Acute Myeloid Leukemia | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

PURPOSE Calcineurin inhibitors (CNI) are standard components of graft-versus-host
disease (GVHD) prophylaxis after hematopoietic cell transplantation (HCT). Prior data …

PURPOSE Hematopoietic cell transplantation (HCT) is curative for hematologic disorders,
but outcomes are historically inferior when using HLA-mismatched donors. Despite …

Posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis has
enabled haploidentical (Haplo) transplantation to be performed with results similar to those …

Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Background Chronic graft-versus-host disease (GVHD) is the leading cause of later illness
and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that …

Background Prevention of graft-versus-host disease (GvHD) without malignant relapse is the
overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate …

Background The majority of patients in need of a hematopoietic-cell transplant do not have a
matched related donor. Data are needed to inform the choice among various alternative …

Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is
predominantly influenced by disease type and status, it is essential to be able to stratify …